FDC introduces stronger versions of Favipiravir Drugs PiFLU, Favenza

30 Oct 2020 Evaluate

FDC has launched new strength variants of its Favipiravir brands - PiFLU and Favenza, used to treat mild to moderate cases of COVID-19 in India. These prescription-only drugs will be available at all retail medical outlets and hospital pharmacies across the country, from November 1, 2020.

The 800mg version of the drugs will help reduce the number of tablets to be taken by any patient by 75%. Currently patients are required to take 18 pills on the first day followed by 8 tablets every day for the next 13 days.

FDC is engaged in manufacture of specialized formulations, and oral rehydration salts (ORS).

FDC Share Price

415.00 0.35 (0.08%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×